Oral Intake of Lactobacilli Can Be Helpful in Symptomatic Bacterial Vaginosis: A Randomized Clinical Study.
Adult
Anti-Infective Agents
/ therapeutic use
Dietary Supplements
/ statistics & numerical data
Female
Humans
Limosilactobacillus reuteri
Lacticaseibacillus rhamnosus
Middle Aged
Probiotics
/ therapeutic use
Prospective Studies
Treatment Outcome
Vagina
/ microbiology
Vaginosis, Bacterial
/ drug therapy
Young Adult
Journal
Journal of lower genital tract disease
ISSN: 1526-0976
Titre abrégé: J Low Genit Tract Dis
Pays: United States
ID NLM: 9704963
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
pubmed:
25
2
2020
medline:
1
5
2021
entrez:
25
2
2020
Statut:
ppublish
Résumé
The aim of the study was to explore a role of oral intake of a mixture of 3 Lactobacillus species in recurrence of bacterial vaginosis (BV). A phase 2 randomized parallel group prospective placebo-controlled study conducted at 7 clinical centers enrolled 18- to 45-years-old women with recent symptomatic BV cured with metronidazole. Within 48 hours after completion of metronidazole therapy, eligible women received 1 capsule of the verum (5.4 billion Lactobacillus crispatus LMG S-29995, Lactobacillus brevis, and Lactobacillus acidophilus in proportion of 60%, 20%, and 20%, respectively), or the placebo supplement 2 times daily for the first 7 days and 1 time daily for the next 8 to 120 days. The primary outcome measure was the percentage of recurrence of BV, which was defined as 3 of 4 Amsel criteria plus abnormal vaginal discharge/vulvar odor during 4 months of intake of the test dietary supplement. Differences between the groups were assessed with Z test for proportions. One hundred sixty-six women were analyzed in the verum (82 patients) and the placebo group (82 patients). Recurrence of BV was documented in 15 (18.3%) of 82 women in the verum group and 27 (32.1%) of 84 in the placebo group (p = .014). Rates of survival without BV rates were higher in the verum group (Cox F test, p = .018). Both verum and placebo supplements were well tolerated. Oral intake of L. crispatus LMG S-29995, L. brevis, and L. acidophilus can significantly decrease percent of recurrences of BV in recently treated women and prolong time to recurrence of the disease.
Identifiants
pubmed: 32091443
doi: 10.1097/LGT.0000000000000518
pii: 00128360-202007000-00010
doi:
Substances chimiques
Anti-Infective Agents
0
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
284-289Références
Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007;109:114–20.
Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34:864–9.
Cherpes TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003;37:319–25.
Wiesenfeld HC, Hillier SL, Krohn MA, et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003;36:663–8.
Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012;9:e1001251.
Donders GG, Van Calsteren K, Bellen G, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG 2009;116:1315–24.
Payne SC, Cromer PR, Stanek MK, et al. Evidence of African-American women's frustrations with chronic, recurrent bacterial vaginosis. J Am Acad Nurse Pract 2010;22:101–8.
Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One 2013;8:e74378.
Centers for disease control and prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines. Bacterial vaginosis. Available at: https://www.cdc.gov/std/tg2015/bv.htm. Accessed July 18, 2018.
Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478–86.
Kaufmann U, Domig KJ, Lippitsch CI, et al. Ability of an orally administered lactobacilli preparation to improve the quality of the neovaginal microflora in male to female transsexual women. Eur J Obstet Gynecol Reprod Biol 2014;172:102–5.
Anoshina TM. Role of microbiota correction in complex treatment of pregnant women with herpesvirus infection. Perinatol Pediatr 2016;4:22–5.
Marschalek J, Farr A, Marschalek ML, et al. Influence of orally administered probiotic Lactobacillus strains on vaginal microbiota in women with breast cancer during chemotherapy: a randomized placebo-controlled double-blinded pilot study. Breast Care 2017;12:335–9.
Laue C, Papazova E, Liesegang A, et al. Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women – a double blind, randomised, controlled clinical pilot trial. Benef Microbes 2018;9:35–50.
Cribby S, Taylor M, Reid G. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis 2008;2008:256490. Published online 2009 Mar 29. Available at: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2662373. Accessed September 11, 2019.
Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis 2012;205:1580–8.
Ahrne S, Nobaek S, Jeppsson B, et al. The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 1998;85:88–94.
Song Y, Kato N, Matsumiya Y, et al. Identification of and hydrogen peroxide production by fecal and vaginal lactobacilli isolated from Japanese women and newborn infants. J Clin Microbiol 1999;37:3062–4.
Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22.
Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297–301.
Random Allocation Software. Available at: https://random-allocation-software.software.informer.com/1.0/. Assessed July 18, 2018.
Turner AN, Carr Reese P, Fields KS, et al. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet Gynecol 2014;211:479.e1–479.e13.
Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 1999;180:1950–6.
Tachedjian G, Aldunate M, Bradshaw CS, et al. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microb 2017;168:782–92.
Bohbot JM, Daraï E, Bretelle F, et al. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J Gynecol Obstet Hum Reprod 2018;47:81–6.
Food and Drug Administration, Center for Drug Evaluation and Research. Bacterial vaginosis: developing drugs for treatment guidance for industry. [Docket Number: FDA-2016-D-1659]. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bacterial-vaginosis-developing-drugs-treatment-guidance-industry. Accessed July 18, 2018.
Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013;56:777–86.